



**NEW IN 2024: Promising Targets Abstracts**  
**Open: September 23, 2024**  
**Deadline: October 7, 2024 at 5:00 PM Central**

To showcase and promote discussion around the most recent and exciting clinical and translational neuropharmacology at ACNP 2024, this year we are holding a new call for *Promising Targets* Abstracts focused on new results from clinical trials and novel pharmacological targets. Abstracts considered ‘Promising Targets’ are those that contain exciting and important findings that were not available prior to the ACNP 2024 August 8<sup>th</sup> General Abstract deadline earlier this year. This Promising Targets deadline is not an extension of the General Abstract submission deadline.

This special session will highlight 6 speakers, each with a 10-min talk plus 10-min discussion.

**All Promising Targets Abstracts must:**

- Include data that could not be analyzed before the ACNP General Abstract deadline, due to unavailability of the data.
- Present significant, ground-breaking, and innovative results.
- Address a novel clinical, translational, or methodological question.
- Apply to clinical/translational neuropharmacology.
- Describe original, previously unpublished work at the time of presentation.
- Obtain management approval prior to submitting the abstract if management approval is required from your company/institution. If the abstract is withdrawn after acceptance for reasons such as lack of management approval, you will be barred from submitting an abstract to ACNP the following year.

**Abstract submission requirements:**

- **Study Design** - Describe the basic study design, e.g., randomized controlled trial, cross-over study, etc. The source of all nonstandard reagents needs to be explicitly stated.
- **Participants** - Indicate number of study subjects and how they were selected and indicate whether subjects include healthy controls.
- **Intervention** - Report the method of administration and the duration of the intervention. Drug identifier must be included.
- **Data collection and analysis** - Summarize the method. Identify the data that could not be analyzed before the General ACNP abstract deadline and indicate the date these data were analyzed.
  - Include all stats
  - Reveal the compound (no “compound X” is allowed)

**Table or Figure**

You may upload one table or figure with your abstract.

Additional Notes for Consideration:

- Accepted Data Blitz and Hot Topics presenters are not eligible to submit for a Promising Targets presentation.
- This session will not qualify for CE/CME.
- Abstracts from this session will not be published in *NPP*.
- The presenting author does not need to have a current invitation to the meeting to submit, and does not need a member to 'chair' their submission. If a presentation is accepted, the presenting author will receive an invitation to the meeting if they do not already have one.

### **Promising Targets Submission Guidelines**

There is a limit of **4700** characters for the abstract and an additional **200** characters for the title. The limits do not include spaces.

Promising Targets abstracts must be submitted by the author (or co-author) or the author's assistant. Submissions by any third party are prohibited.

The College requires all clinical trials in Phase 2 and beyond to be registered in a public registry prior to submission. For more information, please reference the [official statement](#).

**All presenters MUST complete a Conflict of Interest Disclosure form. Industry authors must list their employer as a conflict.**

Accepted presenters must register for the Annual Meeting and pay the registration fee.